Market Access News | pharmaphorum

News

Incyte breaks new ground in anal cancer with EU approval

Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.

News

CBER chief Vinay Prasad to leave FDA once again

For the second time in less than a year, Vinay Prasad has departed from the FDA, after a string of controversial regulatory decisions.

News

China's clears Pfizer GLP-1 ecnoglutide for weight loss

Pfizer has claimed its first regulatory approval for a GLP-1 agonist in obesity, getting a green light in China for Sciwind-sourced ecnoglutide.

News

J&J's Tecvayli claims third national priority FDA approval

J&J claims the FDA's third national priority voucher approval, advancing a Tecvayli-based regimen for multiple myeloma into the second-line setting.

News

Hansa closes on FDA verdict for transplant drug imlifidase

The FDA has started reviewing Hansa's imlifidase for highly sensitised adults needing a kidney transplant, but not in the requested rapid timeframe.

News

Ascendis scores FDA approval for weekly dwarfism drug

Children with achondroplasia will soon have the option of a once-weekly - rather than daily - injection, courtesy of Ascendis' newly approved Yuviwel.

Incyte breaks new ground in anal cancer with EU approval

CBER chief Vinay Prasad to leave FDA once again

China's clears Pfizer GLP-1 ecnoglutide for weight loss

J&J's Tecvayli claims third national priority FDA approval

Hansa closes on FDA verdict for transplant drug imlifidase

Ascendis scores FDA approval for weekly dwarfism drug

UK Health Secretary resigns, sparking leadership speculation

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks